Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes

OBJECTIVE: Our goal was to determine the economic value of azacitidine in Canada compared with conventional care regimens (ccrs), including best supportive care (bsc) and low- or standard-dose chemotherapy plus bsc in the treatment of higher-risk myelodysplastic syndromes (mdss) and acute myeloid le...

Full description

Saved in:
Bibliographic Details
Main Authors: Levy, A.R., Zou, D., Risebrough, N., Buckstein, R., Kim, T., Brereton, N.
Format: Artigo
Language:Inglês
Published: Multimed Inc. 2014
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3921046/
https://ncbi.nlm.nih.gov/pubmed/24523619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.21.1311
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items